cas 1571103-88-2|| where to buy 12,15-Dioxa-2,7,9-triazaheptadecanamide, 17-amino-N-[2-[2-(2-aminoethoxy)ethoxy]ethyl]-8-oxo-, hydrochloride (1:2)

製品名:12,15-Dioxa-2,7,9-triazaheptadecanamide, 17-amino-N-[2-[2-(2-aminoethoxy)ethoxy]ethyl]-8-oxo-, hydrochloride (1:2)

IUPAC Name:3-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-1-{4-[({2-[2-(2-aminoethoxy)ethoxy]ethyl}carbamoyl)amino]butyl}urea dihydrochloride

包装単位	有効在庫	価格（USD）
CM454250-100mg	in stock	Ƕƥ
CM454250-250mg	in stock	ƥƥȺ
CM454250-1g	in stock	ƛƿũ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1571103-88-2 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:1571103-88-2; 分子式:C18H42Cl2N6O6; 融点:-; SMILESコード:Cl.Cl.NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCN; 密度:

: カタログ番号:CM454250; 分子量:509.47; 沸点:; MDL番号:MFCD29035188; 保管方法:

: Tenapanor; FDA has approved XPHOZAH (tenapanor), the first and only phosphate absorption inhibitor, indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

XPHOZAH, with its unique blocking mechanism of action, acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3), reducing phosphate absorption through the paracellular pathway, the primary pathway of phosphate absorption.